939 related articles for article (PubMed ID: 29890622)
41. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes.
Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L
Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189
[No Abstract] [Full Text] [Related]
42. Liquid biopsy in ovarian cancer.
Giannopoulou L; Lianidou ES
Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
[TBL] [Abstract][Full Text] [Related]
43. The pre-analytical phase of the liquid biopsy.
Salvianti F; Gelmini S; Costanza F; Mancini I; Sonnati G; Simi L; Pazzagli M; Pinzani P
N Biotechnol; 2020 Mar; 55():19-29. PubMed ID: 31580920
[TBL] [Abstract][Full Text] [Related]
44. Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs.
Rizzo FM; Meyer T
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):471-483. PubMed ID: 30098711
[TBL] [Abstract][Full Text] [Related]
45. The scope of liquid biopsy in the clinical management of oral cancer.
Baby NT; Abdullah A; Kannan S
Int J Oral Maxillofac Surg; 2022 May; 51(5):591-601. PubMed ID: 34462176
[TBL] [Abstract][Full Text] [Related]
46. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
47. Liquid biopsy and minimal residual disease - latest advances and implications for cure.
Pantel K; Alix-Panabières C
Nat Rev Clin Oncol; 2019 Jul; 16(7):409-424. PubMed ID: 30796368
[TBL] [Abstract][Full Text] [Related]
48. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Zhang X; Ju S; Wang X; Cong H
Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
[TBL] [Abstract][Full Text] [Related]
49. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
50. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?
Kahlert C
Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377
[TBL] [Abstract][Full Text] [Related]
51. Cell-free DNA in blood as a noninvasive insight into the sarcoma genome.
Namløs HM; Boye K; Meza-Zepeda LA
Mol Aspects Med; 2020 Apr; 72():100827. PubMed ID: 31703948
[TBL] [Abstract][Full Text] [Related]
52. Liquid biopsy approach in the management of prostate cancer.
Riaz IB; Wang L; Kohli M
Transl Res; 2018 Nov; 201():60-70. PubMed ID: 29936077
[TBL] [Abstract][Full Text] [Related]
53. Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy.
Rapado-González Ó; López-López R; López-Cedrún JL; Triana-Martínez G; Muinelo-Romay L; Suárez-Cunqueiro MM
Cells; 2019 Dec; 8(12):. PubMed ID: 31861130
[TBL] [Abstract][Full Text] [Related]
54. Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies.
Debattista J; Grech L; Scerri C; Grech G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675253
[TBL] [Abstract][Full Text] [Related]
55. Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis.
Mali SB; Dahivelkar S
Oral Oncol; 2021 Dec; 123():105588. PubMed ID: 34744021
[TBL] [Abstract][Full Text] [Related]
56. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.
Li W; Liu JB; Hou LK; Yu F; Zhang J; Wu W; Tang XM; Sun F; Lu HM; Deng J; Bai J; Li J; Wu CY; Lin QL; Lv ZW; Wang GR; Jiang GX; Ma YS; Fu D
Mol Cancer; 2022 Jan; 21(1):25. PubMed ID: 35057806
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis.
Zhu Y; Zhang H; Chen N; Hao J; Jin H; Ma X
Medicine (Baltimore); 2020 Jan; 99(3):e18581. PubMed ID: 32011436
[TBL] [Abstract][Full Text] [Related]
58. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics.
Geeurickx E; Hendrix A
Mol Aspects Med; 2020 Apr; 72():100828. PubMed ID: 31711714
[TBL] [Abstract][Full Text] [Related]
59. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.
Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S
J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091
[TBL] [Abstract][Full Text] [Related]
60. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
Venesio T; Siravegna G; Bardelli A; Sapino A
Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
